Pfizer Pledges $1.25B for Drug Candidate in Promising But Competitive Area of Immunotherapy
Pfizer’s high most cancers medication are small molecules, however dealmaking has expanded the pharmaceutical big’s portfolio and pipeline with biologic ...
Pfizer’s high most cancers medication are small molecules, however dealmaking has expanded the pharmaceutical big’s portfolio and pipeline with biologic ...
AstraZeneca is paying CSPC Pharmaceutical Group $110 million up entrance to faucet that China-based biotech’s synthetic intelligence-driven expertise for locating...
Copyright © 2024 Agarwood Times.
Agarwood Times is not responsible for the content of external sites.
Copyright © 2024 Agarwood Times.
Agarwood Times is not responsible for the content of external sites.